Northwest Biotherapeutics (NWBT) Initiates Phase III DCVax®-L Brain Cancer Trial in Europe: King's College Hospital in the UK is First Site to Open
5/16/2013 10:36:54 AM
More...
|
Northwest Biotherapeutics (NWBT) Announces That Another Brain Cancer Patient From Phase I/II DCVax®-L Trials Has Surpassed Ten-Year Cancer-Free Survival
4/18/2013 9:59:47 AM
More...
|
Northwest Biotherapeutics (NWBT) Announces $10 Million Registered Direct Offering
4/18/2013 7:36:06 AM
More...
|
Northwest Biotherapeutics (NWBT)'s Phase III Trial With DCVax®-L for Brain Cancer "Adopted" as a National Priority Trial in UK
4/16/2013 10:34:46 AM
More...
|
Northwest Biotherapeutics (NWBT) 2012 Annual Report Shows Strong Progress and Enhancement of Leadership Position
4/9/2013 10:19:59 AM
More...
|
Northwest Biotherapeutics (NWBT) to Review Its Leadership Position in Immune Therapy at the 25th Annual Roth Conference
3/20/2013 8:43:23 AM
More...
|
Northwest Biotherapeutics (NWBT) Receives U.S. Patent on Broad Processes for Producing More Potent Dendritic Cells
3/18/2013 10:22:25 AM
More...
|
Northwest Biotherapeutics (NWBT) Establishes Cross-Border Manufacturing and Distribution for DCVax® in Europe
3/12/2013 10:33:40 AM
More...
|
Northwest Biotherapeutics (NWBT) Provides Guidance on Phase III Trial Enrollment Timing: Completion Expected to be Faster or More Efficient Than Relevant Comparison Trials
3/7/2013 10:58:29 AM
More...
|
Northwest Biotherapeutics (NWBT) Release: DCVax®-Direct Phase I/II Trial for All Inoperable Solid Tumors is Expected to Produce Ongoing Results in 2013
3/5/2013 10:19:24 AM
More...
|
|